Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 6Carcinoma, Renal Cell 5Carcinoma, Transitional Cell 3Thyroid Neoplasms 2Prostatic Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Clear-cell metastatic renal cell carcinoma 2Vulvar Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Seminoma 1Sarcoma 1Rectal Neoplasms 1Rare Diseases 1Pseudomyxoma Peritonei 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Penile Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2trastuzumab deruxtecan 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Taxes 1Sigmoidoscopy 1Radionuclide Imaging 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin 1Magnetic Resonance Imaging 1Ipilimumab 1Ibuprofen 1Epinephrine 1Electrocardiography 1Diphenhydramine 1Dexamethasone 1Colonoscopy 1Carboplatin 1Calcium Dobesilate 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × CTLA-4 Antigen × 30 days × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡